Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation

This study evaluate the potential of plasmatic CXCL-10 (pCXCL-10) as a pre&post transplantation prognostic and diagnostic biomarker of T-cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR) and subclinical rejection (SCR) risk in adult kidney recipients considering BKV and CMV infe...

Descripción completa

Detalles Bibliográficos
Autores: Millan, Olga|||0000-0002-6861-5832, Rovira, J., Guirado, Luis|||0000-0001-5119-3912, Espinosa, C., Budde, K., Sommerer, Claudia|||0000-0001-5080-0979, Piñeiro, Gastón Julio|||0000-0003-3806-4731, Diekmann, Fritz|||0000-0001-6199-3016, Brunet, M.
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:271491
Acceso en línea:https://ddd.uab.cat/record/271491
https://dx.doi.org/urn:doi:10.1016/j.clim.2021.108792
Access Level:acceso abierto
Palabra clave:Kidney transplantation
CXCL-10
Rejection (TCMR ABMR SCR)
BKV
CMV
Biological matrix
Descripción
Sumario:This study evaluate the potential of plasmatic CXCL-10 (pCXCL-10) as a pre&post transplantation prognostic and diagnostic biomarker of T-cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR) and subclinical rejection (SCR) risk in adult kidney recipients considering BKV and CMV infections as possible clinical confounder factors. Twenty-eight of 100 patients included experienced rejection (TCMR:14; ABMR:14); 8 SCR; 13 and 16 were diagnosed with BKV and CMV infection, respectively. Pre-transplantation pCXCL-10 was significantly increased in TCMR and ABMR and post-transplantation in TCMR, ABMR and SCR compared with nonrejectors. All CMV patients showed pCXCL-10 levels above the cutoff values established for rejection whereas the 80% of BKV patients showed pCXCL-10 concentration < 100 pg/mL. pCXCL-10 could improve pre-transplantation patient stratification and immunosuppressive treatment selection according to rejection risk; and after kidney transplantation could be a potential early prognostic biomarker for rejection. Clinical confounding factor in BKV and particularly in CMV patients must be discarded.

Similares en LA Referencia